Cervical Cancer Development, Chemoresistance, and Therapy: a Snapshot of Involvement of MicroRNA

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2021 Aug 28

PMID 34453645

Citations 15

Authors

Tandrima Mitra

Selvakumar Elangovan

Affiliations

Soon will be listed here.

Abstract

Cervical cancer (CC) is one of the leading causes of death in women due to cancer and a major concern in the developing world. Persistent human papilloma virus (HPV) infection is the major causative agent for CC. Besides HPV infection, genetic and epigenetic factors including microRNA (miRNA) also contribute to the malignant transformation. Earlier studies have revealed that miRNAs participate in cell proliferation, invasion and metastasis, angiogenesis, and chemoresistance processes by binding and inversely regulating the target oncogenes or tumor suppressor genes. Based on functions and mechanistic insights, miRNAs have been identified as cellular modulators that have an enormous role in diagnosis, prognosis, and cancer therapy. Signatures of miRNA could be used as diagnostic markers which are necessary for early diagnosis and management of CC. The therapeutic potential of miRNAs has been shown in CC; however, more comprehensive clinical trials are required for the clinical translation of miRNA-based diagnostics and therapeutics. Understanding the molecular mechanism of miRNAs and their target genes has been useful to develop miRNA-based therapeutic strategies for CC and overcome chemoresistance. In this review, we summarize the role of miRNAs in the development, progression, and metastasis of CC as well as chemoresistance. Further, we discuss the diagnostic and therapeutic potential of miRNAs to overcome chemoresistance and treatment of CC.

Citing Articles

Long non-coding RNA H19 promotes cervical cancer development via targeting the microRNA-140/ALDH1A1 axis.

Ming J, Cheng F, Fu Y, Zhang M, Rou Q, Liu K Eur J Med Res. 2025; 30(1):95.

PMID: 39940029 PMC: 11823256. DOI: 10.1186/s40001-025-02350-8.

Comparative Analysis of Digital Transcriptomics Between Pre- and Post-Treatment Samples of Patients with Locally Advanced Cervical Cancer: A Preliminary Study.

Baek S, Mairinger F, Borchert S, Zhao Y, Ratiu D, Mallmann P Curr Issues Mol Biol. 2024; 46(11):12075-12087.

PMID: 39590310 PMC: 11592615. DOI: 10.3390/cimb46110716.

Alterations in miRNA Expression and Their Role in the Pathogenesis of Cervical Cancer.

Feitosa P, Fernandes F, Pereira T, Almeida D, Carvalho A, Almeida V Asian Pac J Cancer Prev. 2024; 25(10):3533-3541.

PMID: 39471019 PMC: 11711363. DOI: 10.31557/APJCP.2024.25.10.3533.

Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.

Sebutsoe X, Tsotetsi N, Jantjies Z, Raphela-Choma P, Choene M, Motadi L Onco Targets Ther. 2024; 17:785-801.

PMID: 39345275 PMC: 11439348. DOI: 10.2147/OTT.S475132.

Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses.

Chauhan P, Pramodh S, Hussain A, Elsori D, Lakhanpal S, Kumar R Front Cell Dev Biol. 2024; 12:1397945.

PMID: 39263322 PMC: 11387185. DOI: 10.3389/fcell.2024.1397945.

References

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Jiang X, Tang H, Chen T . Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2017; 29(1):e7. PMC: 5709533. DOI: 10.3802/jgo.2018.29.e7. View

Sharma G, Dua P, Agarwal S . A Comprehensive Review of Dysregulated miRNAs Involved in Cervical Cancer. Curr Genomics. 2014; 15(4):310-23. PMC: 4133953. DOI: 10.2174/1389202915666140528003249. View

Seppa K, Pitkaniemi J, Malila N, Hakama M . Age-related incidence of cervical cancer supports two aetiological components: a population-based register study. BJOG. 2015; 123(5):772-8. DOI: 10.1111/1471-0528.13754. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Knaul F, Farmer P, Krakauer E, De Lima L, Bhadelia A, Kwete X . Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report. Lancet. 2017; 391(10128):1391-1454. DOI: 10.1016/S0140-6736(17)32513-8. View

Sarenac T, Mikov M . Cervical Cancer, Different Treatments and Importance of Bile Acids as Therapeutic Agents in This Disease. Front Pharmacol. 2019; 10:484. PMC: 6558109. DOI: 10.3389/fphar.2019.00484. View

Zheng G, Peng C, Jia X, Gu Y, Zhang Z, Deng Y . ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH. Mol Cancer. 2015; 14:84. PMC: 4404088. DOI: 10.1186/s12943-015-0357-6. View

Asiaf A, Ahmad S, Mohammad S, Zargar M . Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2013; 23(3):206-24. DOI: 10.1097/CEJ.0b013e328364f273. View

10.

Chaturvedi A . Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010; 46(4 Suppl):S20-6. DOI: 10.1016/j.jadohealth.2010.01.016. View

11.

Fani M, Mahmoodi P, Emadzadeh M, Avan A, Karimi E, Ferns G . Correlation of human papillomavirus 16 and 18 with cervical cancer and their diagnosis methods in Iranian women: A systematic review and meta-analysis. Curr Probl Cancer. 2019; 44(1):100493. DOI: 10.1016/j.currproblcancer.2019.06.008. View

12.

Boyer S, Wazer D, Band V . E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996; 56(20):4620-4. View

13.

Sultana F, English D, Simpson J, Brotherton J, Drennan K, Mullins R . Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. BMC Cancer. 2014; 14:207. PMC: 3994873. DOI: 10.1186/1471-2407-14-207. View

14.

Cohen P, Jhingran A, Oaknin A, Denny L . Cervical cancer. Lancet. 2019; 393(10167):169-182. DOI: 10.1016/S0140-6736(18)32470-X. View

15.

Jonas S, Izaurralde E . Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015; 16(7):421-33. DOI: 10.1038/nrg3965. View

16.

Makarova J, Shkurnikov M, Wicklein D, Lange T, Samatov T, Turchinovich A . Intracellular and extracellular microRNA: An update on localization and biological role. Prog Histochem Cytochem. 2016; 51(3-4):33-49. DOI: 10.1016/j.proghi.2016.06.001. View

17.

Vasudevan S . Posttranscriptional upregulation by microRNAs. Wiley Interdiscip Rev RNA. 2011; 3(3):311-30. DOI: 10.1002/wrna.121. View

18.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

19.

Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui R . Circulating MicroRNAs in Cancer: Potential and Challenge. Front Genet. 2019; 10:626. PMC: 6656856. DOI: 10.3389/fgene.2019.00626. View

20.

Chaiwongkot A, Vinokurova S, Pientong C, Ekalaksananan T, Kongyingyoes B, Kleebkaow P . Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer. 2012; 132(9):2087-94. DOI: 10.1002/ijc.27906. View